1198163-56-2

Basic information

• Product Name: cis-1-(Boc-aMino)-3-cyanocyclohexane, 97%
• Synonyms: cis-1-(Boc-aMino)-3-cyanocyclohexane, 97%;tert-Butyl cis-4-cyanocyclohexylcarbamate
• CAS NO: 1198163-56-2
• Molecular Formula: C12H20N2O2
• Molecular Weight: 224.2994
• Mol File: 1198163-56-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: cis-1-(Boc-aMino)-3-cyanocyclohexane, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: cis-1-(Boc-aMino)-3-cyanocyclohexane, 97%(1198163-56-2)
• EPA Substance Registry System: cis-1-(Boc-aMino)-3-cyanocyclohexane, 97%(1198163-56-2)

Safety Data

• Hazardous Substances Data: 1198163-56-2(Hazardous Substances Data)

Upstream product

• 75-65-0 tert-butyl alcohol 
• 130309-46-5 trans-4-(tert-butoxycarbonylamino)cyclohexane carboxylic acid 
• 53292-90-3 trans-4-(tert-butoxycarbonylamino)cyclohexanoic acid 
• 643067-91-8 1,1-dimethylethyl [trans-4-(aminocarbonyl)cyclohexyl]carbamate 

Relevant articles and documents

FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF

The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

3-oxoisoindoline-1-carboxamides: Potent, state-dependent blockers of voltage-gated sodium channel nav1.7 with efficacy in rat pain models

The voltage-gated sodium channel NaV1.7 is believed to be a critical mediator of pain sensation based on clinical genetic studies and pharmacological results. Clinical utility of nonselective sodium channel blockers is limited due to serious adverse drug effects. Here, we present the optimization, structure-activity relationships, and in vitro and in vivo characterization of a novel series of NaV1.7 inhibitors based on the oxoisoindoline core. Extensive studies with focus on optimization of Na V1.7 potency, selectivity over NaV1.5, and metabolic stability properties produced several interesting oxoisoindoline carboxamides (16A, 26B, 28, 51, 60, and 62) that were further characterized. The oxoisoindoline carboxamides interacted with the local anesthetics binding site. In spite of this, several compounds showed functional selectivity versus Na V1.5 of more than 100-fold. This appeared to be a combination of subtype and state-dependent selectivity. Compound 28 showed concentration- dependent inhibition of nerve injury-induced ectopic in an ex vivo DRG preparation from SNL rats. Compounds 16A and 26B demonstrated concentration-dependent efficacy in preclinical behavioral pain models. The oxoisoindoline carboxamides series described here may be valuable for further investigations for pain therapeutics.

THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R 1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R 2 is methyl; R 3 is a hydrogen atom; and R 4 is a group: -CONR 5 R 6 (in which any one of R 5 and R 6 is a hydrogen atom)].